Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

αCT1 Peptide Weakens Cancerous Glioma Cells | LifeTein Peptide Blog

Glioblastoma (GBM) is the most commonly occurring terminal brain cancer. Due to complications in the brain like the blood brain barrier, methods of treating GBM are few and far between. Therefore, treatment in the region is generally left to specific chemother

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Glioblastoma (GBM) is the most commonly occurring terminal brain cancer. Due to complications in the brain like the blood brain barrier, methods of treating GBM are few and far between. Therefore, treatment in the region is generally left to specific chemotherapeutics like temozolomide (TMZ), which has the unique capability to bypass the brain blood barrier. However, matters become more complicated as many subpopulations of GBM, namely the glioma stem cell populations, are resistant to TMZ. Researchers are looking into ways to bypass this resilience, namely connexin 43 (Cx43) hemichannels that when inhibited by mimetic peptides allow the glioma stem cell populations to be treated significantly more effectively by TMZCx43 mimetic peptides weaken cancer’s resistance to TMZResearchers used LifeTein’s peptide synthesis service to create two mimetic peptides of Cx43, αCT11 and αCT1, to inhibit Cx43 hemichannels and then sensitize the glioma cells and other GBM cell populations to TMZ in a 3D hyaluronic acid and collagen hydrogel-based tumor organoid system. After testing this model extensively, the group found that only the αCT1 peptide in combination with TMZ proved effective in treating the cell lines. It is believed that the αCT1 is more successful due to its cell penetrating sequence when compared to αCT11.Overall, the group emphasizes that the model used does not accurately mimic the cellular heterogeneity of GBM, but the results are a fantastic start and can be used as a tool to further study treatment of this aggressive brain cancer. Further work can optimize this treatment and can hopefully provide a chance for those who have to go against this fatal ailment. Jingru Che, Thomas J. DePalma, Hemamylammal Sivakumar, et al. αCT1 Peptide Sensitizes Glioma Cells to Temozolomide in a Glioblastoma Organoid Platform. Authorea. April 29, 2022.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Live-Cell Imaging and Internalization Studies

FAM-labeled peptides are indispensable tools for tracking cellular uptake and intracellular trafficking. For example, FAM-conjugated ovalbumin peptide (Fam-ova, SIINFEKL) has been widely used to study MHC-I antigen presentation and visualize cytosolic antigen release via confocal microscopy. Similarly, FAM-labeled cell-penetrating peptides (e.g., TAT-derived conjugates) have enabled real-time monitoring of peptide internalization.

Source: lifetein.com ↗

Case Studies and Examples

One notable example is the development of a peptide-based vaccine for the H1N1 influenza virus. Researchers have identified a killer decapeptide (KP) with potent action against the virus. When combined with PADRE, this vaccine has shown improved efficacy in reducing viral levels and improving survival rates in animal models. Applications in Autoimmune Diseases Modulating Immune Responses The PADRE peptide has shown potential in the treatment of autoimmune diseases by modulating immune responses. In conditions such as rheumatoid arthritis and multiple sclerosis, the immune system mistakenly attacks the body’s own tissues. By incorporating PADRE into therapeutic strategies, researchers aim to redirect the immune response, reducing inflammation and tissue damage. Preclinical and Clinical Studies Preclinical studies have demonstrated that PADRE can induce regulatory T-cells (Tregs), which play a crucial role in maintaining immune tolerance. These findings have paved the way for clinical trials exploring PADRE-based therapies for autoimmune diseases. Early results indicate that PADRE can help restore immune balance, offering a promising avenue for treatment. Applications in Allergy Treatments Reducing Allergic Reactions In allergy treatments, the PADRE peptide is used to reduce hypersensitivity reactions. By enhancing the immune system’s ability to tolerate allergens, PADRE can help mitigate symptoms associated with allergic conditions such as asthma and food allergies. Immunotherapy Approaches Immunotherapy approaches incorporating PADRE have shown efficacy in desensitizing patients to specific allergens. For example, PADRE-based vaccines targeting peanut allergies have demonstrated the ability to reduce allergic reactions in clinical trials. These vaccines work by gradually exposing the immune system to the allergen in a controlled manner, promoting tolerance.Find the PADRE Peptide here. Future Directions and Research Expanding Therapeutic Applications Ongoing research aims to expand the therapeutic applications of the PADRE peptide. Scientists are exploring its potential in areas such as transplantation medicine, where PADRE could help prevent organ rejection by modulating the immune response. Additionally, PADRE is being investigated for its role in enhancing the efficacy of DNA vaccines and mRNA vaccines, which have gained prominence in recent years. Innovative Delivery Systems Innovative delivery systems are being developed to improve the stability and efficacy of PADRE-based therapies. These include nanoparticle-based delivery and liposomal formulations, which can enhance the bioavailability and targeted delivery of PADRE to specific tissues. Frequently Asked Questions What is the primary function of the PADRE peptide? The primary function of the PADRE peptide is to bind to MHC class II molecules, enhancing the activation of helper T-cells and boosting immune responses. How is PADRE used in cancer immunotherapy? In cancer immunotherapy, PADRE is incorporated into peptide-based vaccines to improve the presentation of tumor antigens to the immune system, leading to a more effective anti-tumor response. Can PADRE be used in the treatment of autoimmune diseases? Yes, PADRE has shown potential in modulating immune responses in autoimmune diseases, helping to reduce inflammation and tissue damage. What are some examples of PADRE’s applications in allergy treatments? PADRE is used in immunotherapy approaches to reduce allergic reactions, such as in vaccines targeting peanut allergies, which promote immune tolerance to the allergen. What future research directions are being explored for PADRE? Future research is exploring PADRE’s potential in transplantation medicine, DNA and mRNA vaccines, and innovative delivery systems like nanoparticle-based and liposomal formulations.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Purification and Stability

Azide-containing peptides should be purified by standard reverse-phase HPLC and stored desiccated at -20°C. The azide group is generally stable under these conditions but may be reduced to a primary amine by strong reducing agents such as dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP), a consideration if your peptide also contains disulfide bonds. Find out about high-speed RUSH synthesis.

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →